Emergent BioSolutions clinical trials
The registry lists 51 studies whose lead sponsor is Emergent BioSolutions or one of 2 companies grouped under it. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.
Our grouping of 3 registry names, not the registry’s. See them and correct one ↓
- 51studies on the registry
- 7open to participants now
- 3reach primary completion within a year
Get an email when these change. Save the Emergent BioSolutions studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Emergent BioSolutions’ studies test, most studies first; none is open now — 13 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- ACAM20001 in phase 30 open · 4
- AV79091 in phase 30 open · 4
- Biothrax1 in phase 30 open · 2
- zanolimumab2 in phase 30 open · 2
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- IB10011 in phase 30 open · 1
Show 3 moreShow fewer
Coming up
3 of Emergent BioSolutions’ studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- 2JJul
- 1AAug
- SSep
- OOct
- NNov
All 3
- Jul 2027Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNCT03569514
- Jul 2027A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNCT03569553
- Aug 2027VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionNCT01374984
Add all 3 to your calendar (.ics) → With an account.
All 51 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 508
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 126
By the year each study started; 6 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Emergent BioSolutions.
- Emergent BioSolutions47 studiesSame company
Something wrong?
- Cangene Corporation3 studies →Acquired — became part of Emergent BioSolutions, Feb 21, 2014 · source ↗
Something wrong?
- Emergent Product Development Seattle LLC1 study →Divested — left Emergent BioSolutions, Aug 1, 2016 · source ↗
Something wrong?
Focus areas
Conditions Emergent BioSolutions leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →
- VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionEnrolling by invitationNCT01374984
- Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNot yet recruitingNCT07478471
- Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNot yet recruitingNCT02177721Phase 4
- Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNot yet recruitingNCT03569514
- A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNot yet recruitingNCT03569553
- BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric PatientsEnrolling by invitationNCT02051062Phase 4
- Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.Not yet recruitingNCT07268612
- CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaTerminatedNCT00893516Phase 2
- Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy AdultsCompletedNCT05377255Phase 1
- VELOCITY: An Anthrax Vaccine Clinical StudyCompletedNCT03877926Phase 3
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyCompletedNCT04067011Phase 2
- Ciprofloxacin BioThrax Co-Administration StudyCompletedNCT01753115Phase 2
- A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy AdultsCompletedNCT04661839Phase 1
- A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsCompletedNCT05142306Phase 1
- Study of SIAN Nasal Spray in Healthy AdultsCompletedNCT05194358Phase 1
- Universal Influenza A Vaccine in Healthy AdultsCompletedNCT05155319Phase 1
- Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsCompletedNCT05935917Phase 1
- Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsCompletedNCT00679172Phase 2
- Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsCompletedNCT01491607Phase 3
- Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)CompletedNCT00928577
- Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsCompletedNCT00053482Phase 2
- Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)TerminatedNCT01311674Phase 3
- ACAM2000® Myopericarditis RegistryCompletedNCT01395082
- Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy SubjectsTerminatedNCT02696291Phase 1
- Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsCompletedNCT01263691Phase 1
- Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)CompletedNCT03624946Phase 1
- Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ACompletedNCT03315104Phase 2
- Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military PersonnelCompletedNCT01540929
- Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected AdultsTerminatedNCT02771730Phase 1
- VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVCompletedNCT01158157Phase 3
- A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047TerminatedNCT03160339Phase 1
- Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy SubjectsCompletedNCT02061358Phase 1
- VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIVCompletedNCT02443623Phase 4
- A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsCompletedNCT01770743Phase 2
- Safety Surveillance Study of ACAM2000® Vaccinia VaccineCompletedNCT00927719
- Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB MuscleCompletedNCT00636519Phase 1
- Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedCompletedNCT02339155Phase 4
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)CompletedNCT00845650Phase 1/2
- Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationCompletedNCT00053495Phase 2
- Safety Study of 7 Botulinum Antitoxin Serotypes Derived From HorsesCompletedNCT00360737Phase 1
- A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesCompletedNCT01979406Phase 1
- HuMax-CD4 in Non-Cutaneous T-Cell LymphomaCompletedNCT00877656Phase 2/3
- Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1CompletedNCT01006798Phase 1
- BioThrax® (Anthrax) Vaccine in Pregnancy RegistryCompletedNCT01653392
- Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)CompletedNCT01202695Phase 1
- BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum AntitoxinCompletedNCT02055183
- Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumCompletedNCT00448253Phase 1
- Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia BWithdrawnNCT02048111Phase 3
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions
- Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant PatientsCompletedNCT00722332Phase 4
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions
- Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella InfectionApproved for marketingNCT00338442
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions